Year: 2024
Type: dissertation
Abstract: Neonatal hypoxic-ischemic (HI) brain injury and resulting encephalopathy (HIE) is the most important contributor to the global burden of infant death and disability. Therapeutic hypothermia (HT) is the established standard of care, yet prognosis remains poor for infants despite treatment, with an additional portion of the HIE population ineligible for cooling or in a low- or middle-income country where the impact of cooling is negligible. Thus, the current challenge lies in delineating the mechanisms that underlie HI pathogenesis, such that targeted interventions can be developed and used as adjuvants or alternatives to HT. Calcium (Ca2+)-dependent excitotoxicity is a postulated hub of pathophysiological responses in neonatal HI, implicating the ryanodine receptor-2 (RyR2) on the endoplasmic reticulum. RyR2 is the most potent regulator of intracellular Ca2+ signaling and is highly sensitive to pathological perturbations in the cellular environment. I thus hypothesized that RyR2 antagonism is a clinically relevant intervention for the treatment of neonatal HI brain injury. To test this, I first carried out two meta-analyses of clinical data that demonstrated the potential for adjuvant therapy to enhance the effectiveness of HT, and implicated Ca2+ as a potential therapeutic target in HIE infants. Then using a neonatal mouse model of HI brain injury, I found that RyR2 loss-of-function reduced brain infarction, neuronal cell loss, astrocyte activation and cerebrovascular alterations, and improved early reflex and sensorimotor neurobehaviour, and long-term learning, memory and motor coordination. I then demonstrated that both pre- and post-treatment with clinically available RyR antagonist, dantrolene, improved short- and long-term morphological and neurobehavioural deficits following HI brain injury. Dantrolene treatment was associated with the downregulation of pro-apoptotic signaling and upregulation of pro-survival signaling, and was found to exert neuroprotection to the same extent as HT when administered as a monotherapy or adjuvant. Finally, post-treatment with specific RyR2 inhibitor, R-carvedilol, was found to mitigate short- and long-term brain infarction and functional impairments following HI brain injury. Taken together, this thesis demonstrates that RyR2 contributes to HI brain injury and is an important therapeutic target. This work also proposes two clinically available drugs that hold promise for repurposing as neuroprotectants and advancing care for infants affected by HIE.
Source: TSpace (University of Toronto)
Author: Ovcjak, Andrea
Institution: University of Toronto
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7226043660
